New double-drug therapy gives fresh hope to Brits with oesophagus cancer - Daily Mail

New trial results suggest that patients given the immunotherapy medicine tislelizumab alongside chemotherapy are likely to live much longer than those given chemotherapy alone.

A double-drug therapy offers the best hope yet for thousands of Britons with cancer of the oesophagus. New trial results suggest that patients given the immunotherapy medicine tislelizumab alongside… [+5409 chars]

full article...